BackUltragenyx Pharmaceutical Overview

Ultragenyx Pharmaceutical Gross Profit

Gross Profit analysis for RARE.

Quarterly Gross Profit

$106.00M
↓ 4.19% YoY

As of Mar 31, 2026

Annual Gross Profit (TTM)

$550.82M
↑ 9.54% YoY

Trailing 12 months ending Mar 31, 2026

Average Gross Profit (Comparison Companies)

Gross Profit History

Gross Profit Comparison

Annual Gross Profit Growth Rate (%)

Annual Gross Profit Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin